ClinicalTrials.gg
TerminatedNCT04252586Updated Aug 8, 2022Results posted

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

A Phase 3 interventional study of GWP42003-P in Rett Syndrome and RTT, sponsored by Jazz Pharmaceuticals. Terminated at 31 sites in 6 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Enrollment
22nd of 34
21 · median 32
Started
2020
with 3 others
Phase 3
11 of 55
2 open now
Registered
29th of 55
by date
Lead sponsor
2 of 55
Jazz Pharmaceuticals

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2020, is one of 11 in phase 3, and was the 29th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in participants with Rett syndrome.

03

Conditions studied

  • Rett Syndrome
  • RTT

Browse trials for

Keywords

  • Cannabidiol
  • CBD
  • Epidiolex
  • GWP42003-P
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has completed all scheduled visits of the treatment phase of the randomized controlled trial (RCT), GWND18064 (NCT03848832), and has transitioned to open-label extension (OLE) by the point of RCT follow-up
  • Participant (if possessing adequate understanding, in the investigator's opinion) and/or the participant(s)/legal representative is willing and able to give /assent for participation in the trial.
  • Participant and the participant's caregiver are willing and able (in the investigator's opinion) to comply with all trial requirements (including the completion of all caregiver assessments by the same caregiver throughout the trial).
  • Ability to swallow the medicinal product (IMP) provided as a liquid solution, or the ability for the IMP to be delivered via gastrostomy (G) or nasogastric (NG) feeding tube (only G- or NG-tubes made from polyurethane or silicon are allowed).
  • Participant and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
  • Participant and/or parent(s)/legal representative is willing to allow the participant's primary care practitioner (if the participant has one) and consultant (if the participant has one) to be notified of participation in the trial, if the primary care practitioner/consultant is different from the investigator.

Exclusion criteria

Exclusion Criteria:

  • Participant meets the withdrawal criteria (including abnormal laboratory values), in the investigator's opinion.
  • Participant met during the RCT the criteria for permanent IMP discontinuation (unless in the case of an adverse event [AE], if the AE was not considered related with the IMP; participants that met (ALT)/aspartate aminotransferase (AST) elevations discontinuation criteria must be excluded).
  • Females of , unless willing to ensure that they or their partner use a highly effective method of (e.g., combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, or transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, or implantable], intrauterine devices/hormone-releasing systems, bilateral tubal occlusion, vasectomized partner, sexual abstinence during the trial and for 3 months after the last dose
  • Participant has been previously enrolled and dosed in this trial.
  • Participant is unwilling to abstain from donation of blood during the trial.
  • Male participants who are fertile (i.e., after puberty unless permanently sterile by bilateral orchidectomy) and with a partner of childbearing potential unless agree to ensure that they use male contraception (e.g., condom) or remain sexually abstinent during the trial and for 3 months after the last dose
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    GWP42003-P

    100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).

    Drug: GWP42003-P

Interventions

  • GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring

    Also known as: Cannabidiol, CBD, Epidiolex, CBD-OS

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs

    Adverse events (AEs) were defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings when relevant) or diagnosis or worsening of a pre-existing condition that occurs during the study. TEAEs were defined as the AEs that started or worsened in severity or seriousness following the first dose of GWP42003-P. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 16 (Day 767) in the OLE

  2. Number of Participants With Treatment-emergent Clinical Laboratory Parameters From the Baseline at Any Time Post-dose

    Treatment-emergent clinical parameters were defined as the following: Treatment-emergent alanine transferase (ALT) \> 3×upper limit of normal (ULN), \> 5×ULN and \> 8×ULN; Treatment-emergent aspartate aminotransferase (AST) \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN and either bilirubin \> 2×ULN or international normalized ratio (INR) \> 1.5.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

  3. Number of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose

    Potentially clinically significant vital sign values of blood pressure (BP) were defined as sitting systolic BP (mmHg) change: \< -20 or \> 20 mmHg and sitting diastolic BP change: \< -10 or \> 10 mmHg. Vital sign measurements were taken in a sitting position at rest for 5 minutes. Blood pressure readings were recorded using the same arm throughout the trial, when possible.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE

  4. Number of Participants With Clinically Significant Changes in the Vital Sign Values of Pulse Rate From the Baseline at Any Time Post-dose

    Potentially clinically significant vital sign values of pulse rate were defined as pulse rate change: \< -10 or \> 10 beats per minute. Vital sign measurements were taken in a sitting position at rest for 5 minutes.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE

  5. Number of Participants With Clinically Significant Percent Change in Body Weight From the Baseline at Any Time Post-dose

    Clinically significant body weight changes were defined as the percent change in body weight (≤7% change or ≥7% change).

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

  6. Number of Participants With At Least One Post Open Label Extension Baseline Flagged ECG Result

    Electrocardiogram assessments were performed for QTcB and QTcF \>450 msec, \>480 msec, and \>500 msec. QTcB = corrected QT interval with Bazette correction. QTcF = QTc corrected by Fridericia.

    Time frame: Visit 4 (Day 29) up to Visit 15 (Day 739) in the OLE

  7. Number of Participants With Any Changes In Menstruation Cycle at Any Time Post-dose

    Participants were evaluated for any changes to typical menstrual cycles, duration of menstrual cycles, and typical strength of the menstrual cycles during the study.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

  8. Number of Participants With Suicidal Ideation or Behavior at the Baseline and at Any Time Post-dose

    Suicidal ideation and behavior was assessed by the investigator via a clinical interview with the caregiver. The questionnaire included following questions: Has the child expressed any wish to be dead?, Has the child made any suicide attempts?, Has the child shown any non-suicidal self-injurious behavior? The responses were recorded as Yes/No.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

  9. Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment

    Blood samples were collected to assess changes in serum IGF-1 levels. A negative mean change from baseline indicates a reduction in IGF-1 levels.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

  10. Number of Participants With Changes in Tanner Staging at the Baseline and at End of Treatment

    Pubic hair growth and breast development of all adolescents were assessed by the investigator or caregiver using Tanner Staging categorization from 1 to 5. Stage 1- No glandular tissue; areola follows skin contours of chest; No pubic hair Stage 2- Breast bud forms; areola begins to widen; a small amount of long, downy hair with slight pigmentation on labia majora Stage 3- Breast begins to become more elevated and extends beyond borders of the areola, which continues to widen but remains in contour with surrounding breast; Hair becomes more coarse and curly and begins to extend laterally Stage 4- Increased breast size and elevation; areola and papilla form a secondary mound projecting from the contour of the surrounding breast; Adult-like hair quality, extending across pubis but sparing medial thighs Stage 5- Breast reaches final adult size; areola returns to the contour of the surrounding breast, with a projecting central papilla; Hair extends to medial surface of the thigh.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

Secondary outcomes

  1. Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment

    RSBQ is a caregiver-completed questionnaire that assesses the overall condition (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true". " Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse-scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity. A negative mean change from baseline indicates an improvement in overall condition.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

  2. Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment

    CGI-I is a 7-point scale that requires the clinician to assess whether a patient's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. The mean continuous CGI-I score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher mean scores indicate worse condition.

    Time frame: Visit 14 (Day 729) in the OLE

  3. Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment

    CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This was rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 =severely ill; or 7 = extremely ill. The mean continuous CGI-S score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher scores indicate more severe disease.

    Time frame: Visit 14 (Day 729) in the OLE

  4. Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment

    CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales:bedtime resistance (score range 6-18), sleep onset delay (range 1-3), sleep duration (range 3-9), sleep anxiety (range 4-12), night wakings (range 3-9), parasomnias (range 7-21), sleep-disordered breathing (range 3-9), daytime sleepiness (range 8-24). The 33 items range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32, 3=fall asleep, 2=very sleepy, 1=not sleepy. A score of 3 indicates greater severity; however, 6 items (1-Goes to bed at same time; 3-Falls asleep in own bed; 26-Wakes by himself; 2-Falls asleep in 20 minutes; 10-Sleeps the right amount; 11-Sleeps same amount each day) are reverse scored. The total summed score ranges from 33 to 99, with higher scores indicating disturbed sleep behavior. A negative mean change from baseline indicates improvement in sleep.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

  5. Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment

    MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. The MBA-9 includes 9 items (Regression of motor skills; Poor eye/social contact; Lack of sustained interest; Does not reach for objects or people; Chewing difficulties; Speech disturbance; Hand clumsiness; Dystonia; and Hypertonia/rigidity). For each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. A negative mean change from baseline indicates improvement in behavior.

    Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE

07

Results

Posted Aug 8, 2022
Limitations and caveats
This trial was terminated due to enrollment challenges and the COVID-19 pandemic. Due to early termination and participants withdrawal, the number of participants was small and the length of treatment was reduced.

Participant flow

A total of 21 participants who had previously participated in the randomized, double-blind, placebo-controlled trial GWND18064 (NCT03848832) entered this open label extension study.

Participant flow — Overall Study
MilestoneGWP42003-P
Started21
Completed0
Not completed21
Withdrew: Withdrawal by parent/guardian3
Withdrew: Adverse event1
Withdrew: Death2
Withdrew: Study terminated by sponsor4
Withdrew: Sponsor request10
Withdrew: Did not complete treatment period1

Outcome measures

PrimaryNumber of Participants With Any Treatment-emergent Adverse Events (TEAEs), Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs

Adverse events (AEs) were defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings when relevant) or diagnosis or worsening of a pre-existing condition that occurs during the study. TEAEs were defined as the AEs that started or worsened in severity or seriousness following the first dose of GWP42003-P. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 16 (Day 767) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs
ParticipantsGWP42003-P
Any TEAE19
Treatment-related TEAEs7
TEAEs leading to discontinuation3
Treatment-related TEAE leading to discontinuation1
Serious TEAEs5
Treatment-related serious TEAEs0
PrimaryNumber of Participants With Treatment-emergent Clinical Laboratory Parameters From the Baseline at Any Time Post-dose

Treatment-emergent clinical parameters were defined as the following: Treatment-emergent alanine transferase (ALT) \> 3×upper limit of normal (ULN), \> 5×ULN and \> 8×ULN; Treatment-emergent aspartate aminotransferase (AST) \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN and either bilirubin \> 2×ULN or international normalized ratio (INR) \> 1.5.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Clinical Laboratory Parameters From the Baseline at Any Time Post-dose
ParticipantsGWP42003-P
Treatment-emergent ALT >3xULN1
Treatment-emergent ALT >5xULN0
Treatment-emergent ALT >8xULN0
Treatment-emergent AST >3xULN0
Treatment-emergent AST >5xULN0
Treatment-emergent AST >8xULN0
Treatment-emergent ALT or AST >3xULN1
Treatment-emergent ALT or AST >5xULN0
Treatment-emergent ALT or AST >8xULN0
Treatment-emergent ALT or AST > 3×ULN and either bilirubin > 2×ULN or INR > 1.50
PrimaryNumber of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose

Potentially clinically significant vital sign values of blood pressure (BP) were defined as sitting systolic BP (mmHg) change: \< -20 or \> 20 mmHg and sitting diastolic BP change: \< -10 or \> 10 mmHg. Vital sign measurements were taken in a sitting position at rest for 5 minutes. Blood pressure readings were recorded using the same arm throughout the trial, when possible.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose
ParticipantsGWP42003-P
Systolic BP Change <-20 mmHg, Baseline4
Systolic BP Change <-20 mmHg, Day 292
Systolic BP Change <-20 mmHg, Day 571
Systolic BP Change <-20 mmHg, Day 851
Systolic BP Change <-20 mmHg, Day 1412
Systolic BP Change <-20 mmHg, Day 1972
Systolic BP Change <-20 mmHg, Day 2810
Systolic BP Change <-20 mmHg, Day 3650
Systolic BP Change <-20 mmHg, End of Treatment (up to Day 729)1
Systolic BP Change <-20 mmHg, Day 7391
Systolic BP Change >20 mmHg, Baseline1
Systolic BP Change >20 mmHg, Day 291
Systolic BP Change >20 mmHg, Day 573
Systolic BP Change >20 mmHg, Day 852
Systolic BP Change >20 mmHg, Day 1410
Systolic BP Change >20 mmHg, Day 1970
Systolic BP Change >20 mmHg, Day 2810
Systolic BP Change >20 mmHg, Day 3650
Systolic BP Change >20 mmHg, End of Treatment (up to Day 729)2
Systolic BP Change >20 mmHg, Day 7390
Diastolic BP Change <-10 mmHg, Baseline7
Diastolic BP Change <-10 mmHg, Day 294
Diastolic BP Change <-10 mmHg, Day 574
Diastolic BP Change <-10 mmHg, Day 852
Diastolic BP Change <-10 mmHg, Day 1413
Diastolic BP Change <-10 mmHg, Day 1973
Diastolic BP Change <-10 mmHg, Day 2810
Diastolic BP Change <-10 mmHg, Day 3650
Diastolic BP Change <-10 mmHg, End of Treatment (up to Day 729)3
Diastolic BP Change <-10 mmHg, Day 7390
Diastolic BP Change >10 mmHg, Baseline4
Diastolic BP Change >10 mmHg, Day 299
Diastolic BP Change >10 mmHg, Day 574
Diastolic BP Change >10 mmHg, Day 854
Diastolic BP Change >10 mmHg, Day 1413
Diastolic BP Change >10 mmHg, Day 1971
Diastolic BP Change >10 mmHg, Day 2810
Diastolic BP Change >10 mmHg, Day 3650
Diastolic BP Change >10 mmHg, End of Treatment (up to Day 729)5
Diastolic BP Change >10 mmHg, Day 7390
PrimaryNumber of Participants With Clinically Significant Changes in the Vital Sign Values of Pulse Rate From the Baseline at Any Time Post-dose

Potentially clinically significant vital sign values of pulse rate were defined as pulse rate change: \< -10 or \> 10 beats per minute. Vital sign measurements were taken in a sitting position at rest for 5 minutes.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in the Vital Sign Values of Pulse Rate From the Baseline at Any Time Post-dose
ParticipantsGWP42003-P
Pulse Rate Change <-10beats/min, Baseline9
Pulse Rate Change <-10beats/min, Day 298
Pulse Rate Change <-10beats/min, Day 577
Pulse Rate Change <-10beats/min, Day 857
Pulse Rate Change <-10beats/min, Day 1412
Pulse Rate Change <-10beats/min, Day 1975
Pulse Rate Change <-10beats/min, Day 2811
Pulse Rate Change <-10beats/min, Day 3651
Pulse Rate Change <-10beats/min, End of Treatment (up to Day 729)6
Pulse Rate Change <-10beats/min, Day 7390
Pulse Rate Change >10beats/min, Baseline5
Pulse Rate Change >10beats/min, Day 292
Pulse Rate Change >10beats/min, Day 573
Pulse Rate Change >10beats/min, Day 853
Pulse Rate Change >10beats/min, Day 1413
Pulse Rate Change >10beats/min, Day 1971
Pulse Rate Change >10beats/min, Day 2810
Pulse Rate Change >10beats/min, Day 3650
Pulse Rate Change >10beats/min, End of Treatment (up to Day 729)4
Pulse Rate Change >10beats/min, Day 7392
PrimaryNumber of Participants With Clinically Significant Percent Change in Body Weight From the Baseline at Any Time Post-dose

Clinically significant body weight changes were defined as the percent change in body weight (≤7% change or ≥7% change).

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Percent Change in Body Weight From the Baseline at Any Time Post-dose
ParticipantsGWP42003-P
Weight Percent Change ≤7%, Baseline1
Weight Percent Change ≤7%, End of Treatment (up to Day 729)1
Weight Percent Change ≥7%, Baseline8
Weight Percent Change ≥7%, End of Treatment (up to Day 729)10
PrimaryNumber of Participants With At Least One Post Open Label Extension Baseline Flagged ECG Result

Electrocardiogram assessments were performed for QTcB and QTcF \>450 msec, \>480 msec, and \>500 msec. QTcB = corrected QT interval with Bazette correction. QTcF = QTc corrected by Fridericia.

Time frame:
Visit 4 (Day 29) up to Visit 15 (Day 739) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With At Least One Post Open Label Extension Baseline Flagged ECG Result
ParticipantsGWP42003-P
QTcB Interval, Aggregate > 450 msec, Day 294
QTcB Interval, Aggregate > 450 msec, Day 570
QTcB Interval, Aggregate > 450 msec, Day 854
QTcB Interval, Aggregate > 450 msec, Day 1410
QTcB Interval, Aggregate > 450 msec, Day 1970
QTcB Interval, Aggregate > 450 msec, Day 3650
QTcB Interval, Aggregate > 450 msec, End of Treatment (up to Day 729)4
QTcB Interval, Aggregate > 450 msec, Day 7390
QTcB Interval, Aggregate > 480 msec, Day 290
QTcB Interval, Aggregate > 480 msec, Day 570
QTcB Interval, Aggregate > 480 msec, Day 851
QTcB Interval, Aggregate > 480 msec, Day 1410
QTcB Interval, Aggregate > 480 msec, Day 1970
QTcB Interval, Aggregate > 480 msec, Day 3650
QTcB Interval, Aggregate > 480 msec, End of Treatment (up to Day 729)1
QTcB Interval, Aggregate > 480 msec, Day 7390
QTcB Interval, Aggregate > 500 msec, Day 290
QTcB Interval, Aggregate > 500 msec, Day 570
QTcB Interval, Aggregate > 500 msec, Day 850
QTcB Interval, Aggregate > 500 msec, Day 1410
QTcB Interval, Aggregate > 500 msec, Day 1970
QTcB Interval, Aggregate > 500 msec, Day 3650
QTcB Interval, Aggregate > 500 msec, End of Treatment (up to Day 729)0
QTcB Interval, Aggregate > 500 msec, Day 7390
QTcF Interval, Aggregate > 450 msec, Day 290
QTcF Interval, Aggregate > 450 msec, Day 570
QTcF Interval, Aggregate > 450 msec, Day 851
QTcF Interval, Aggregate > 450 msec, Day 1410
QTcF Interval, Aggregate > 450 msec, Day 1970
QTcF Interval, Aggregate > 450 msec, Day 3650
QTcF Interval, Aggregate > 450 msec, End of Treatment (up to Day 729)0
QTcF Interval, Aggregate > 450 msec, Day 7390
QTcF Interval, Aggregate > 480 msec, Day 290
QTcF Interval, Aggregate > 480 msec, Day 570
QTcF Interval, Aggregate > 480 msec, Day 850
QTcF Interval, Aggregate > 480 msec, Day 1410
QTcF Interval, Aggregate > 480 msec, Day 1970
QTcF Interval, Aggregate > 480 msec, Day 3650
QTcF Interval, Aggregate > 480 msec, End of Treatment (up to Day 729)0
QTcF Interval, Aggregate > 480 msec, Day 7390
QTcF Interval, Aggregate > 500 msec, Day 290
QTcF Interval, Aggregate > 500 msec, Day 570
QTcF Interval, Aggregate > 500 msec, Day 850
QTcF Interval, Aggregate > 500 msec, Day 1410
QTcF Interval, Aggregate > 500 msec, Day 1970
QTcF Interval, Aggregate > 500 msec, Day 3650
QTcF Interval, Aggregate > 500 msec, End of Treatment (up to Day 729)0
QTcF Interval, Aggregate > 500 msec, Day 7390
PrimaryNumber of Participants With Any Changes In Menstruation Cycle at Any Time Post-dose

Participants were evaluated for any changes to typical menstrual cycles, duration of menstrual cycles, and typical strength of the menstrual cycles during the study.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Any Changes In Menstruation Cycle at Any Time Post-dose
ParticipantsGWP42003-P
Any change to typical cycle, Yes; Day 11
Any change to typical cycle, No; Day 11
Any change to typical cycle; Day 1 Unknown/Missing19
Typical duration of menstruation cycle, <3 days; Day 10
Typical duration of menstruation cycle, 3-7 days; Day 11
Typical duration of menstruation cycle, >7 days; Day 10
Typical duration of menstruation cycle; Day 1 Unknown/Missing20
Typical strength of menstruation cycle, Light; Day 11
Typical strength of menstruation cycle, Moderate; Day 10
Typical strength of menstruation cycle, Heavy; Day 10
Typical strength of menstruation cycle, Other; Day 10
Typical strength of menstruation cycle; Day 1 Unknown/Missing20
Any change to typical cycle, Yes; End of Treatment (up to Day 729)3
Any change to typical cycle, No; End of Treatment (up to Day 729)3
Any change to typical cycle; End of Treatment (up to Day 729) Unknown/Missing12
Typical duration of menstruation cycle, <3 days; End of Treatment (up to Day 729)0
Typical duration of menstruation cycle, 3-7 days; End of Treatment (up to Day 729)3
Typical duration of menstruation cycle, >7 days; End of Treatment (up to Day 729)0
Typical duration of menstruation cycle; End of Treatment (up to Day 729) Unknown/Missing15
Typical strength of menstruation cycle, Light; End of Treatment (up to Day 729)1
Typical strength of menstruation cycle, Heavy; End of Treatment (up to Day 729)2
Typical strength of menstruation cycle, Moderate; End of Treatment (up to Day 729)0
Typical strength of menstruation cycle, Other; End of Treatment (up to Day 729)0
Typical strength of menstruation cycle; End of Treatment (up to Day 729) Unknown/Missing15
PrimaryNumber of Participants With Suicidal Ideation or Behavior at the Baseline and at Any Time Post-dose

Suicidal ideation and behavior was assessed by the investigator via a clinical interview with the caregiver. The questionnaire included following questions: Has the child expressed any wish to be dead?, Has the child made any suicide attempts?, Has the child shown any non-suicidal self-injurious behavior? The responses were recorded as Yes/No.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behavior at the Baseline and at Any Time Post-dose
ParticipantsGWP42003-P
Has the child expressed any wish to be dead? Yes, Baseline0
Has the child expressed any wish to be dead? No, Baseline16
Has the child expressed any wish to be dead? Unknown/Missing, Baseline5
Has the child expressed any wish to be dead? Yes, End of Treatment (up to Day 729)0
Has the child expressed any wish to be dead? No, End of Treatment (up to Day 729)18
Has the child made any suicide attempts? Yes, Baseline0
Has the child made any suicide attempts? No, Baseline16
Has the child made any suicide attempts? Unknown/Missing, Baseline5
Has the child made any suicide attempts? Yes, End of Treatment (up to Day 729)0
Has the child made any suicide attempts? No, End of Treatment (up to Day 729)18
Has the child shown any non-suicidal self-injurious behavior? Yes, Baseline0
Has the child shown any non-suicidal self-injurious behavior? Yes, usual behavior, Baseline3
Has the child shown any non-suicidal self-injurious behavior? Yes, worsening behavior, Baseline0
Has the child shown any non-suicidal self-injurious behavior? No, Baseline13
Has the child shown any non-suicidal self-injurious behavior? Unknown/Missing, Baseline5
Has the child shown any non-suicidal self-injurious behavior? Yes, End of Treatment (up to Day 729)0
Has child shown any non-suicidal self-injurious behavior? Yes, usual behavior, EOT (up to Day 729)4
Has child shown any non-suicidal self-injurious behavior? Yes, worse behavior, EOT (up to Day 729)0
Has child shown any non-suicidal self-injurious behavior? No, End of Treatment (up to Day 729)14
PrimaryMean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment

Blood samples were collected to assess changes in serum IGF-1 levels. A negative mean change from baseline indicates a reduction in IGF-1 levels.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Mean · units on a scale
Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment
units on a scaleGWP42003-P
Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment-41.1 ± 100.77
PrimaryNumber of Participants With Changes in Tanner Staging at the Baseline and at End of Treatment

Pubic hair growth and breast development of all adolescents were assessed by the investigator or caregiver using Tanner Staging categorization from 1 to 5. Stage 1- No glandular tissue; areola follows skin contours of chest; No pubic hair Stage 2- Breast bud forms; areola begins to widen; a small amount of long, downy hair with slight pigmentation on labia majora Stage 3- Breast begins to become more elevated and extends beyond borders of the areola, which continues to widen but remains in contour with surrounding breast; Hair becomes more coarse and curly and begins to extend laterally Stage 4- Increased breast size and elevation; areola and papilla form a secondary mound projecting from the contour of the surrounding breast; Adult-like hair quality, extending across pubis but sparing medial thighs Stage 5- Breast reaches final adult size; areola returns to the contour of the surrounding breast, with a projecting central papilla; Hair extends to medial surface of the thigh.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Count of participants · Participants
Number of Participants With Changes in Tanner Staging at the Baseline and at End of Treatment
ParticipantsGWP42003-P
Baseline, Tanner Stage 16
Baseline, Tanner Stage 23
Baseline, Tanner Stage 31
Baseline, Tanner Stage 42
Baseline, Tanner Stage 54
Baseline, Tanner Stage Missing5
End of Treatment (up to Day 729), Tanner Stage 14
End of Treatment (up to Day 729), Tanner Stage 22
End of Treatment (up to Day 729), Tanner Stage 31
End of Treatment (up to Day 729), Tanner Stage 43
End of Treatment (up to Day 729), Tanner Stage 53
End of Treatment (up to Day 729), Tanner Stage Missing5
SecondaryMean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment

RSBQ is a caregiver-completed questionnaire that assesses the overall condition (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true". " Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse-scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity. A negative mean change from baseline indicates an improvement in overall condition.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Mean · units on a scale
Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment
units on a scaleGWP42003-P
Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment-7.4 ± 14.93
SecondaryMean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment

CGI-I is a 7-point scale that requires the clinician to assess whether a patient's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. The mean continuous CGI-I score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher mean scores indicate worse condition.

Time frame:
Visit 14 (Day 729) in the OLE
Reported as:
Mean · score on a scale
Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment
score on a scaleGWP42003-P
Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment3.3 ± 1.15
SecondaryMean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment

CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This was rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 =severely ill; or 7 = extremely ill. The mean continuous CGI-S score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher scores indicate more severe disease.

Time frame:
Visit 14 (Day 729) in the OLE
Reported as:
Mean · score on a scale
Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment
score on a scaleGWP42003-P
Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment4.3 ± 0.96
SecondaryMean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment

CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales:bedtime resistance (score range 6-18), sleep onset delay (range 1-3), sleep duration (range 3-9), sleep anxiety (range 4-12), night wakings (range 3-9), parasomnias (range 7-21), sleep-disordered breathing (range 3-9), daytime sleepiness (range 8-24). The 33 items range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32, 3=fall asleep, 2=very sleepy, 1=not sleepy. A score of 3 indicates greater severity; however, 6 items (1-Goes to bed at same time; 3-Falls asleep in own bed; 26-Wakes by himself; 2-Falls asleep in 20 minutes; 10-Sleeps the right amount; 11-Sleeps same amount each day) are reverse scored. The total summed score ranges from 33 to 99, with higher scores indicating disturbed sleep behavior. A negative mean change from baseline indicates improvement in sleep.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Mean · units on a scale
Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment
units on a scaleGWP42003-P
Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment-3.0 ± 6.87
SecondaryMean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment

MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. The MBA-9 includes 9 items (Regression of motor skills; Poor eye/social contact; Lack of sustained interest; Does not reach for objects or people; Chewing difficulties; Speech disturbance; Hand clumsiness; Dystonia; and Hypertonia/rigidity). For each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. A negative mean change from baseline indicates improvement in behavior.

Time frame:
Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Reported as:
Mean · units on a scale
Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment
units on a scaleGWP42003-P
Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment0.7 ± 5.19

Adverse events

Collected over Adverse event data were collected from baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 16 (Day 767) in the OLE.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P2/21 (9.5%)5/21 (23.8%)19/21 (90.5%)
Most frequent serious events
Most frequent serious events
EventGWP42003-P
Respiratory failureRespiratory, thoracic and mediastinal disorders2/21
Rett SyndromeCongenital, familial and genetic disorders1/21
COVID-19Infections and infestations1/21
Lower respiratory tract infectionInfections and infestations1/21
Postoperative wound infectionInfections and infestations1/21
Generalised tonic-clonic seizureNervous system disorders1/21
Status epilepticusNervous system disorders1/21
Respiratory arrestRespiratory, thoracic and mediastinal disorders1/21
Most frequent other events
Showing 10 of 19
Most frequent other events
EventGWP42003-P
VomitingGastrointestinal disorders7/21
DiarrhoeaGastrointestinal disorders4/21
PyrexiaGeneral disorders4/21
Upper respiratory tract infectionInfections and infestations3/21
Monocyte count decreasedInvestigations3/21
Decreased appetiteMetabolism and nutrition disorders3/21
SeizureNervous system disorders3/21
IrritabilityPsychiatric disorders3/21
NeutropeniaBlood and lymphatic system disorders2/21
Otitis mediaInfections and infestations2/21

Baseline characteristics

Baseline characteristics were assessed in the Safety Analysis Set which was defined as all participants who received at least one dose of GWP42003-P in the study.

Age, Continuous
Age, Continuous(years)GWP42003-P
Mean10.2 ± 5.59
Age, Customized
Age, Customized(Participants)GWP42003-P
2-5 years6
6-12 years9
13-19 years6
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P
Female21
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GWP42003-P
Hispanic or Latino1
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GWP42003-P
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported0
08

Study locations

31 sites
  • Clinical Trial Site
    Birmingham, Alabama 35294-0021, United States
  • Clinical Trial Site
    La Jolla, California 92093, United States
  • Clinical Trial Site
    Aurora, Colorado 80045, United States
  • Clinical Trial Site
    Chicago, Illinois 60612, United States
  • Clinical Trial Site
    Baltimore, Maryland 21205, United States
  • Clinical Trial Site
    Boston, Massachusetts 02115, United States
  • Clinical Trial Site
    Saint Paul, Minnesota 55101, United States
  • Clinical Trial Site
    Saint Louis, Missouri 63110-1093, United States
  • Clinical Trial Site
    Bronx, New York 10467, United States
  • Clinical Trial Site
    Cincinnati, Ohio 45229, United States
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Trial Site
    Greenwood, South Carolina 29646, United States
  • Clinical Trial Site
    Nashville, Tennessee 37232, United States
  • Clinical Trial Site
    Houston, Texas 77030, United States
  • Clinical Trial Site
    Perth, Australia
  • Clinical Trial Site
    South Brisbane, Australia
  • Clinical Trial Site
    Toronto, Canada
  • Clinical Trial Site
    Vancouver, Canada
  • Clinical Trial Site
    Genova, Italy
  • Clinical Trial Site
    Messina, Italy
  • Clinical Trial Site
    Milano, Italy
  • Clinical Trial Site
    Rome, Italy
  • Clinical Trial Site
    Siena, Italy
  • Clinical Trial Site #1
    Barcelona, Spain
  • Clinical Trial Site #2
    Barcelona, Spain
  • Clinical Trial Site #1
    Madrid, Spain
  • Clinical Trial Site #2
    Madrid, Spain
  • Clinical Trial Site
    Valencia, Spain
  • Clinical Trial Site
    Edinburgh, United Kingdom
  • Clinical Trial Site
    Liverpool, United Kingdom
  • Clinical Trial Site
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jun 2021, 15 months.

Results were first posted in Aug 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2020
First posted
Feb 5, 2020
StartActual
Feb 28, 2020
Primary completionActual
Jun 9, 2021
CompletionActual
Jun 9, 2021
Results first posted
Aug 8, 2022
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04252586
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Feb 28, 2020
Primary completion
Jun 9, 2021
Completion
Jun 9, 2021
Results posted
Aug 8, 2022
Last update
Aug 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion